
Recent FDA approval of nirsevimab and clesrovimab have transformed RSV prevention in infants, prompting new recommendations from the CDC and AAP and replacing the long-standing role of palivizumab.
PharmD, professor of pediatrics at the University of Georgia College of Pharmacy
Recent FDA approval of nirsevimab and clesrovimab have transformed RSV prevention in infants, prompting new recommendations from the CDC and AAP and replacing the long-standing role of palivizumab.
Published: September 29th 2025 | Updated: